This document provides guidance to industry on good pharmacovigilance practices andpharmacoepidemiologic assessment of observational data regarding drugs, including biologicaldrug products (excluding blood and blood components). Specifically, this document providesguidance on (1) safety signal identification, (2) pharmacoepidemiologic assessment and safetysignal interpretation, and (3) pharmacovigilance plan development.
Submit comments on this guidance document electronically via docket ID: FDA-2013-S-0610 - Specific Electronic Submissions Intended For FDA's Dockets Management Staff (i.e., Citizen Petitions, Draft Proposed Guidance Documents, Variances, and other administrative record submissions)
If unable to submit comments online, please mail written comments to:
Food and Drug Administration
5630 Fishers Lane, Rm 1061
Rockville, MD 20852
All comments should be identified with the title of the guidance.